This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies
Organizer(s): Christian Klein, Mark S. Cragg and Germaine Fuh
Date: April 07 - 11, 2019
Location: Beaver Run Resort, Breckenridge, CO, USA
Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG and Roche
Summary of Meeting:
Over the last 20 years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.
Scholarship Deadline: December 11 2018
Discounted Abstract Deadline: December 11 2018
Abstract Deadline: January 9 2019
Discounted Registration Deadline: February 6 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AbbVie Inc.Bioverativ TherapeuticsImmunoGen, Inc.Incyte CorporationMerck & Co., Inc.MorphoSys AGRoche
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

CytomX Therapeutics, Inc.

Denali Therapeutics Inc.

Genmab B.V.

ImmunoGen, Inc.

Lundbeck

NovImmune SA

Regeneron Pharmaceuticals, Inc.

Roche

Xencor, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI145248-01
Funding for this conference was made possible (in part) by 1R13AI145248-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found